About one-third of sponsors in a new survey say trial results summaries (TRS) are becoming more important as a way to better engage patients.
Sponsors, especially larger ones, understand TRS is an important foundation to a strong patient engagement program, says Thomas Wicks, chief strategy officer for TrialScope, who conducted the survey. Of the 86 respondents, 71 self-identified as pharmaceutical drug sponsors, while 15 said they were biotech sponsors.
Providing a TRS is “the right thing to do, but it’s also beneficial [from a business perspective] to engage with patients,” Wicks says. “It should be seen as an opportunity, not a chore.”
However, regulatory requirements remained the top driver, with 22% of respondents citing them among the factors pushing TRS. Other factors include:
- 20% cited attempting to stay apace of evolving transparency trends
- 15% cited patient engagement initiatives and/or organizational ethics commitments
It’s not always easy to produce a simple TRS, Wicks acknowledges. “It takes resources, it takes money, [and] it’s quite challenging,” he says. His firm doesn’t help write TRS, but it does provide ways to better distribute them once they are finished.
Wicks advocates that a TRS website/portal have several characteristics, including:
- Unbiased and non-promotional context
- Multi-language accessibility
- Automated import of clinical information
- Direct communication with trial participants for sharing updated information
More than 60% of survey respondents were planning to post more than 20 studies over the next 24 months, suggesting more respondents were large or mid-size sponsors, Wicks conjectures. TRS are currently most commonly produced for Phase II and Phase III studies, according to the TrialScope survey.
For more information, contact Wicks at email@example.com.
Author: Michael Causey